| Name | Title | Contact Details |
|---|
Moda Technology Partners is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bacharach Institute and Rehabilitation is a Pomona, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
H2h Solutions, Inc is a Wixom, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardinal Innovations Healthcare is the leading provider of managed care services in the U.S. Cardinal Innovations, the nations largest specialty health plan and the pioneer of a unique managed healthcare model, incorporates a community-based model of care management, a network of highly-skilled providers and local support partners to improve the health and wellness of plan members. Cardinal Innovations serves members through Medicaid, state and county-funded plans and supports a variety of initiatives for Veterans and their families through centralized call center services and other collaborative initiatives.
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.